All articles tagged with #remdesivir
The Partners trial in Ituri has enrolled its first patients to test remdesivir and MBP134 against Bundibugyo Ebola, aiming for 700–1,000 participants; started six weeks after the WHO declared a public health emergency, with hopes to reduce mortality despite frontline pay and supply challenges.
A WHO-backed trial in Bunia, Ituri province, Congo, launches to test remdesivir, the MBP134 antibody, or both for Bundibugyo Ebola patients, with 28‑day survival tracking; the first participant is enrolled and the study is expected to last 3–6 months, potentially expanding to high‑risk groups later. The outbreak has diagnosed over 1,400 cases and at least 438 deaths, amid mistrust, overcrowded treatment centers, and security challenges that complicate the response.
WHO convened expert groups to evaluate candidate vaccines and therapeutics for Bundibugyo virus disease (BDV) outbreaks in the Democratic Republic of the Congo and Uganda. With no BDV-specific licensed treatments or vaccines, experts prioritized three therapeutics for evaluation in clinical trials—MBP134, Maftivimab, and remdesivir—with combination therapy also considered, and looked at obeldesivir for post‑exposure prophylaxis. The most promising BDV vaccine candidates are a single‑dose rVSV Bundibugyo vaccine (7–9 months to readiness for trials) and ChAdOx1 Bundibugyo (2–3 months to efficacy testing), while Ervebo should not be used outside carefully designed research settings to assess BDV protection. The initiative emphasizes ethics, rapid trial design, accelerated access to supplies, and strengthened outbreak control as trials proceed.
The Ebola Bundibugyo outbreak in the DRC and Uganda has prompted fast-tracked, WHO-backed clinical trials of two therapies—MBP134 antibodies and remdesivir—with government approvals pending; MBP134 shows strong animal data and remdesivir has prior antiviral use, as researchers aim to quickly assess effectiveness against this Ebola species amid thousands of suspected cases and deaths.
Israel is experiencing a new wave of COVID-19 cases, leading to a critical shortage of the antiviral drug Remdesivir, which is essential for treating severe cases. Hospitals report an increase in hospitalizations and criticize the Health Ministry's procurement policies. The ministry has announced that new supplies of the drug are expected to arrive soon.
The University of Derby is leading a £1.2m study to test whether the anti-viral drug remdesivir can cure people with "long Covid". The nine-month trial involves about 100 participants who have experienced long Covid symptoms for over two years. Long Covid symptoms include extreme fatigue, breathlessness, palpitations, and brain fog. The study aims to shed light on potential treatments for long Covid, as there are currently no confirmed treatments available. Participants will undergo tests before and after receiving remdesivir to monitor improvements, including exercise tolerability and body scans to assess inflammation reduction. If successful, a larger study may be conducted next year to further understand how to manage the condition effectively.